53250-82-1

Basic information

• Product Name: 4-(Methylsulfonamido)aniline
• Synonyms: 4-(Methylsulfonamido)aniline;N-(4-AMINOPHENYL)METHANESULFONAMIDE;N-(4-Amino-phenyl)methanesulfonamide ,97%;N-(4-aminophenyl)methanesulfonamide(SALTDATA: FREE);4-(Methylsulfonamido)
• CAS NO: 53250-82-1
• Molecular Formula: C₇H₁₀N₂O₂S
• Molecular Weight: 186.23
• Product Categories: Amines and Anilines
• Mol File: 53250-82-1.mol
• Article Data: 22

Chemical Properties

• Melting Point: 116-117.5 °C
• Boiling Point: 362.2 °C at 760 mmHg
• Flash Point: 172.8 °C
• Appearance: /
• Density: 1.408 g/cm³
• Vapor Pressure: 1.97E-05mmHg at 25°C
• Refractive Index: 1.637
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.90±0.10(Predicted)
• CAS DataBase Reference: 4-(Methylsulfonamido)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Methylsulfonamido)aniline(53250-82-1)
• EPA Substance Registry System: 4-(Methylsulfonamido)aniline(53250-82-1)

Safety Data

• Hazardous Substances Data: 53250-82-1(Hazardous Substances Data)

Usage

Uses

N-(4-Aminophenyl)methanesulfonamide is a useful intermediate for the large-scale preparation of amino-methanesulfonylaminobenzenesulfonamide.

InChI:InChI=1/C7H10N2O2S/c1-12(10,11)9-7-4-2-6(8)3-5-7/h2-5,9H,8H2,1H3

Upstream product

• 71026-66-9 N-(tert-butoxycarbonyl)-1,4-phenylenediamine 
• 77167-09-0 N-[p-(acetylamino)phenyl]methanesulfonamide 
• 100-01-6 4-nitro-aniline 
• 124-63-0 methanesulfonyl chloride 
• 106-50-3 1,4-phenylenediamine 
• 5825-62-7 N-(4-nitrophenyl)methanesulfonamide 

Downstream Products

• 1027016-73-4 2-Chloro-N-(4-methanesulfonylamino-phenyl)-nicotinamide 
• 108792-17-2 (4-Methanesulfonylimino-cyclohexa-2,5-dienylidene)-carbamic acid methyl ester 
• 108792-25-2 2-amino-6-methoxycarbonylaminobenzothiazole 
• 108792-12-7 N-methanesulphonyl-N'-pivaloyl-1,4-benzoquinone-imine 
• 108792-01-4 N-dichloroacetyl-N'-methanesulphonyl-1,4-benzoquinone-imine 
• 96-75-3 2-amino-5-nitro-benzenesulfonic acid 
• 515153-01-2 C₂₄H₂₂N₄O₄S 
• 1208872-50-7 C₂₂H₂₃BrN₂O₄S 
• 1208872-42-7 ethyl 3-(5-(4-bromothiophen-2-yl)-1-(4-(methylsulfonamido)phenyl)-1H-pyrrol-2-yl)propanoate 
• 1208872-44-9 ethyl 3-(5-(4-(2-methyl-1H-imidazol-1-yl)thiophen-2-yl)-1-(4-(methylsulfonamido)phenyl)-1H-pyrrol-2-yl)propanoate 
• 1208872-51-8 C₂₆H₂₈N₄O₄S 
• 1208317-88-7 3-(5-(4-(2-methyl-1H-imidazol-1-yl)thiophen-2-yl)-1-(4-(methylsulfonamido)phenyl)-1H-pyrrol-2-yl)propanoic acid 
• 1208317-92-3 3-(5-(4-(2-methyl-1H-imidazol-1-yl)phenyl)-1-(4-(methylsulfonamido)phenyl)-1H-pyrrol-2-yl)propanoic acid 
• 575476-22-1 N₂,N₄-bis[(4-methylsulfonylamino)phenyl]-5-fluoro-2,4-pyrimidinediamine 

Relevant articles and documents

Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds

Targeting the protein-protein interaction (PPI) between nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1) is a potential therapeutic strategy to control diseases involving oxidative stress. Here, six classes of known small-molecule Keap1-Nrf2 PPI inhibitors were dissected into 77 fragments in a fragment-based deconstruction reconstruction (FBDR) study and tested in four orthogonal assays. This gave 17 fragment hits of which six were shown by X-ray crystallography to bind in the Keap1 Kelch binding pocket. Two hits were merged into compound 8 with a 220-380-fold stronger affinity (Ki = 16 μM) relative to the parent fragments. Systematic optimization resulted in several novel analogues with Ki values of 0.04-0.5 μM, binding modes determined by X-ray crystallography, and enhanced microsomal stability. This demonstrates how FBDR can be used to find new fragment hits, elucidate important ligand-protein interactions, and identify new potent inhibitors of the Keap1-Nrf2 PPI.

5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors

We are concerned with the development of novel anti-infectives with dual antibacterial and antiretroviral activities for MRSA/HIV-1 co-infection. To achieve this goal, we exploited for the first time the mechanistic function similarity between the bacterial RNA polymerase (RNAP) "switch region" and the viral non-nucleoside reverse transcriptase inhibitor (NNRTI) binding site. Starting from our previously discovered RNAP inhibitors, we managed to develop potent RT inhibitors effective against several resistant HIV-1 strains with maintained or enhanced RNAP inhibitory properties following a structure-based design approach. A quantitative structure-activity relationship (QSAR) analysis revealed distinct molecular features necessary for RT inhibition. Furthermore, mode of action (MoA) studies revealed that these compounds inhibit RT noncompetitively, through a new mechanism via closing of the RT clamp. In addition, the novel RNAP/RT inhibitors are characterized by a potent antibacterial activity against S. aureus and in cellulo antiretroviral activity against NNRTI-resistant strains. In HeLa and HEK 293 cells, the compounds showed only marginal cytotoxicity.